| Tag |
First Indicator |
Second Indicator |
Subfields |
| LEADER |
00000cam a22000007i 4500 |
| 001 |
in00005773604 |
| 005 |
20260327180322.8 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
240908s2025 enk ob 001 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|e rda
|c YDX
|d OPELS
|d OCLCO
|d EMU
|d YDX
|d OCLCL
|d SFB
|
| 020 |
|
|
|a 9780443302565
|q electronic book
|
| 020 |
|
|
|a 0443302561
|q electronic book
|
| 020 |
|
|
|z 9780443190810
|
| 020 |
|
|
|z 044319081X
|
| 035 |
|
|
|a (OCoLC)1455105355
|
| 050 |
|
4 |
|a QP364.7
|b .A53 2025
|
| 082 |
0 |
4 |
|a 573.8/5
|2 23/eng/202409024
|
| 049 |
|
|
|a TXAM
|
| 245 |
0 |
0 |
|a Anandamide in health and disease /
|c volume editor, Bernard Le Foll.
|
| 264 |
|
1 |
|a London ;
|a San Diego, CA :
|b Academic Press,
|c [2025]
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
0 |
|
|a Molecular mediators in health and disease: how cells communicate
|
| 500 |
|
|
|a Contributors: Yalitza Azucena Alvarado Ramírez, Balapal S. Basavarajappa, Sheldon Bereznick, Laura M. Best, M. Belen Blasco, Isabelle Boileau, Roberto Colangeli, Michelle De Pol, Vincenzo Di Marzo, Jacklynn M. Fitzgerald, Renaud Gom, Andrea M. Herrera Solís, Cecilia J. Hillard, Nathan J. Kolla, Sara Liane Kroll, Bernard Le Foll, F. Markus Leweke, Shamantha Lora, Raesham Mahmood, Allison Matthews...Pasindu Wickramarachchi.
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 520 |
|
|
|a A complete reference on the roles of anandamide in health and disease states. Following the characteristics of the series, this book provides a comprehensive overview of the effects of the mediator on human health. The book is divided into two parts, the first of which provides background information on biology, regulation, synthesis and degradation and modulation of anandamide. The second part is dedicated to covering the role of anandamide in various diseases. A comprehensive panel of authors cover several somatic and psychiatric disorders, such as anxiety disorders, mood disorders, psychosis and substance use disorders. Additionally, the role of anandamide across epilepsy, Alzheimer's disease, and digestive conditions is explored. This work is the perfect reference for bioscience researchers seeking to understand anandamide pharmacology, biochemistry, cellular, and molecular biology. Clinicians may also be interested in better understanding the wide-ranging health effects of the mediator.
|
| 588 |
|
|
|a Description based on online resource; title from digital title page (viewed on December 16, 2024).
|
| 505 |
0 |
|
|a Front Cover -- Anandamide in Health and Disease -- Molecular Mediators in Health and Disease: How Cells Communicate -- Anandamide in Health and Disease Molecular Mediators in Health and Disease: How Cells Communicate -- Copyright -- Contents -- Contributors -- An introduction to the role of anandamide in health and disease -- Disclosures -- References -- Series preface -- I -- Introduction to anandamide -- 1 -- Regulation of the levels of anandamide and its bioactive congeners by biosynthesis and degradation -- 1. Introduction. Discovery and biological role of anandamide and its congeners -- 2. Biosynthesis of anandamide and its congeners -- 3. Inactivation of anandamide and its congeners -- 3.1 Hydrolysis -- 3.2 Oxidation of anandamide by various enzymatic pathways -- 4. SNPs of the main enzymes specifically involved in N-acyl-ethanolamine biosynthesis and degradation -- 5. Therapeutic manipulation of anandamide and N-acyl-ethanolamine levels through pharmacological and dietary interventions -- 6. Conclusions -- References -- 2 -- Imaging the endocannabinoid enzyme fatty acid amide hydrolase in the living human brain -- 1. Harvesting the therapeutic potential of fatty acid amide hydrolase -- 2. Fatty acid amide hydrolase -- 3. The development of FAAH inhibitors -- 4. Trials with FAAH inhibitors in humans -- 5. Positron emission tomography as a tool to investigate FAAH in vivo -- 6. Development of PET radiotracers for FAAH -- 7. PET radiotracers for FAAH not yet translated to human -- 8. Human PET imaging of [11C]CURB for the key endocannabinoid enzyme FAAH -- 9. Conclusions and future direction -- References -- 3 -- Anandamide: From modulation of neuronal excitation to antimicrobial activities-What is in common? -- 1. Introduction -- 2. Biosynthesis of Anandamide and its metabolism -- 2.1 Anandamide production.
|
| 505 |
8 |
|
|a 6.3 Anandamide interferes with daughter cell separation during Staphylococcus aureus cell division -- 6.4 Anandamide alters bacterial membrane properties -- 6.4.1 Anandamide induces immediate changes in the bacterial membrane potential -- 6.4.2 Anandamide reduces membrane incorporation of the membrane fluidity probe laurdan -- 6.4.3 Anandamide increases the proportion of cardiolipin in the bacterial membrane -- 6.5 Anandamide inhibits membrane ATPase activity -- 6.6 Anandamide reduces the cell wall teichoic acid content -- 6.7 Antibiofilm effect of anandamide -- 6.7.1 Role of altered membrane potential for the antibiofilm effect of anandamide -- 6.7.2 The role of reduced RNAIII transcript levels for the antibiofilm effect of anandamide -- 6.7.3 The role of reduced autolysin and increased ClpXP activities for the antibiofilm effect of anandamide -- 6.7.4 Anandamide reduces exopolysaccharide production but increases extracellular DNA (eDNA) -- 6.8 Anandamide sensitizes MRSA and MDRSA to antibiotics -- 7. Antifungal effects of anandamide -- 8. Conclusions -- References -- II -- Anandamide in diseases -- 4 -- Anandamide and mood disorders -- 1. Introduction -- 2. Fundamentals of N-arachidonoylethanolamine as a signaling molecule -- 2.1 AEA biosynthesis and catabolism -- 2.2 Receptor targets of AEA:CB1R -- 2.3 Receptor targets of AEA: Transient receptor potential vanilloid 1 -- 2.4 Interactions between CB1R and TRPV1 signaling -- 2.5 Other receptor targets of AEA -- 3. AEA-mediated signaling in brain regions essential for mood regulation -- 3.1 AEA signaling in the amygdala -- 3.2 AEA signaling: PFC -- 3.3 AEA signaling: Hippocampus -- 3.4 Interactions between AEA and dopamine signaling -- 4. AEA-mediated regulation of the hypothalamic-pituitary adrenal axis -- 5. Preclinical, behavioral studies.
|
| 505 |
8 |
|
|a 5.1 AEA-mediated regulation of behavioral responses to acute stress -- 5.2 Role of AEA in brain plasticity associated with chronic stress and trauma -- 5.3 Role of AEA in fear memories -- 5.4 Role of AEA in depressive behaviors -- 6. Human studies -- 6.1 Circulating AEA concentrations -- 6.1.1 Effects of acute psychological and physiological stress on circulating AEA concentrations -- 6.1.2 Depression -- 6.1.3 Anxiety -- 6.1.4 Posttraumatic stress disorder -- 6.2 Genetic studies -- 7. Neurobiological associations -- 7.1 Amygdala -- 7.2 Hippocampus -- 7.3 Prefrontal cortex -- 7.4 Striatum -- 8. Clinical studies with FAAH inhibitors -- 9. Conclusions -- References -- 5 -- Anandamide and anxiety -- 1. Introduction -- 2. Studies in healthy adults -- 2.1 Genetic influences on anandamide levels (FAAH C385A) -- 2.2 Anandamide levels in biological samples -- 2.3 Pharmacological manipulation of anandamide levels (FAAH inhibition) -- 3. Anxiety disorders -- 3.1 Genetic influences on anandamide levels (FAAH C385A) -- 3.2 Anandamide levels in biological samples -- 3.3 Pharmacological manipulation of anandamide levels (FAAH inhibition) -- 4. Clinical populations other than anxiety disorders -- 4.1 Genetic influences on anandamide levels (FAAH C385A) -- 4.2 Anandamide levels in biological samples -- 4.3 Pharmacological manipulation of anandamide levels (FAAH inhibition) -- 5. Overall conclusions: Is there a relationship between anandamide and anxiety? -- References -- 6 -- Anandamide and disease. Role in stress, fear, and PTSD -- 1. Posttraumatic Stress Disorder -- 2. Mechanisms underlying PTSD -- 2.1 Stress reactivity -- 2.2 Fear extinction -- 3. Treatment of PTSD -- 4. Cannabinoids as treatments for PTSD -- 4.1 Cannabis use in PTSD -- 4.2 Cannabinoids in stress studies -- 4.3 Cannabinoids in fear conditioning studies.
|
| 650 |
|
0 |
|a Neurotransmitters.
|
| 650 |
|
6 |
|a Neurotransmetteurs.
|
| 655 |
|
7 |
|a Electronic books.
|2 local
|
| 700 |
1 |
|
|a Le Foll, Bernard,
|e editor.
|
| 710 |
2 |
|
|a ScienceDirect (Online service)
|
| 776 |
0 |
8 |
|c Original
|z 044319081X
|z 9780443190810
|w (OCoLC)1419866921
|
| 856 |
4 |
0 |
|u http://proxy.library.tamu.edu/login?url=https://www.sciencedirect.com/science/book/9780443190810
|z Connect to the full text of this electronic book
|t 0
|
| 955 |
|
|
|a Elsevier ScienceDirect 2026-2027
|
| 994 |
|
|
|a 92
|b TXA
|
| 999 |
f |
f |
|i 59b649ee-f14f-4fa5-90b8-7a15c95e089b
|s 036d747f-836c-4a0c-a063-465249054d6b
|t 0
|
| 952 |
f |
f |
|a Texas A&M University
|b College Station
|c Electronic Resources
|s www_evans
|d Available Online
|t 0
|e QP364.7 .A53 2025
|h Library of Congress classification
|
| 998 |
f |
f |
|a QP364.7 .A53 2025
|t 0
|l Available Online
|